- Home
- BASE vs ABVX Comparison
BASE vs ABVX Comparison
Compare BASE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- ABVX
- Stock Information
- Founded
- BASE 2011
- ABVX 2013
- Country
- BASE United States
- ABVX France
- Employees
- BASE N/A
- ABVX N/A
- Industry
- BASE EDP Services
- ABVX
- Sector
- BASE Technology
- ABVX
- Exchange
- BASE Nasdaq
- ABVX Nasdaq
- Market Cap
- BASE 834.0M
- ABVX 722.3M
- IPO Year
- BASE 2021
- ABVX N/A
- Fundamental
- Price
- BASE $19.25
- ABVX $9.50
- Analyst Decision
- BASE Buy
- ABVX Strong Buy
- Analyst Count
- BASE 13
- ABVX 6
- Target Price
- BASE $23.31
- ABVX $36.50
- AVG Volume (30 Days)
- BASE 261.2K
- ABVX 82.3K
- Earning Date
- BASE 12-03-2024
- ABVX 09-09-2024
- Dividend Yield
- BASE N/A
- ABVX N/A
- EPS Growth
- BASE N/A
- ABVX N/A
- EPS
- BASE N/A
- ABVX N/A
- Revenue
- BASE $198,818,000.00
- ABVX $9,676,417.00
- Revenue This Year
- BASE $17.65
- ABVX $31.67
- Revenue Next Year
- BASE $15.17
- ABVX $1,189.66
- P/E Ratio
- BASE N/A
- ABVX N/A
- Revenue Growth
- BASE 21.00
- ABVX 100.87
- 52 Week Low
- BASE $13.53
- ABVX $8.75
- 52 Week High
- BASE $32.00
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- BASE 69.59
- ABVX 34.50
- Support Level
- BASE $15.65
- ABVX $10.27
- Resistance Level
- BASE $20.11
- ABVX $10.79
- Average True Range (ATR)
- BASE 0.60
- ABVX 0.36
- MACD
- BASE 0.26
- ABVX -0.05
- Stochastic Oscillator
- BASE 80.74
- ABVX 8.16
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.